Alcon (NYSE:ALC) this week posted second-quarter results that beat the overall consensus on Wall Street and raised its full-year guidance.
The Geneva-based eye care company reported profits of $151 million, or 31¢ per share, on sales of $2.1 billion for the three months ended June 30, for a sales growth of 74.79% compared with Q2 2020.
Adjusted to exclude one-time items, earnings per share were 56¢, 11¢ ahead of The Street, where analysts were looking for sales of $1.96 billion.
“Our second-quarter performance demonstrates the strength and resilience of our businesses, with our highest quarterly sales and earnings since our spin-off,” CEO David Endicott said in a news release. “Strong commercial execution behind our new product launches resulted in all sales categories in Surgical and Vision Care posting growth over 2019, notwithstanding the continued impact of COVID-19.”
“The healthy recovery in the business underlies our confidence in driving top-line growth with continued innovation and the growing demand for eye care. With the ongoing expansion of our manufacturing capacity, we remain focused on maintaining a steady stream of product flow as we expand our portfolio and respond to market demand.”
Alcon adjusted its full-year outlook to be in the sales range of $8.0 to $8.2 billion with a core diluted EPS in the range of $2.00 to $2.10.
Shares in ALC were up 12.09% to $79.99 apiece at market open.